TY - JOUR
T1 - Machine Learning Improves Upon Clinicians' Prediction of End Stage Kidney Disease
AU - Chuah, Aaron
AU - Walters, Giles
AU - Christiadi, Daniel
AU - Karpe, Krishna
AU - Kennard, Alice
AU - Singer, Richard
AU - Talaulikar, Girish
AU - Ge, Wenbo
AU - Suominen, Hanna
AU - Andrews, T. Daniel
AU - Jiang, Simon
N1 - Publisher Copyright:
Copyright © 2022 Chuah, Walters, Christiadi, Karpe, Kennard, Singer, Talaulikar, Ge, Suominen, Andrews and Jiang.
PY - 2022/3/16
Y1 - 2022/3/16
N2 - Background and Objectives: Chronic kidney disease progression to ESKD is associated with a marked increase in mortality and morbidity. Its progression is highly variable and difficult to predict. Methods: This is an observational, retrospective, single-centre study. The cohort was patients attending hospital and nephrology clinic at The Canberra Hospital from September 1996 to March 2018. Demographic data, vital signs, kidney function test, proteinuria, and serum glucose were extracted. The model was trained on the featurised time series data with XGBoost. Its performance was compared against six nephrologists and the Kidney Failure Risk Equation (KFRE). Results: A total of 12,371 patients were included, with 2,388 were found to have an adequate density (three eGFR data points in the first 2 years) for subsequent analysis. Patients were divided into 80%/20% ratio for training and testing datasets. ML model had superior performance than nephrologist in predicting ESKD within 2 years with 93.9% accuracy, 60% sensitivity, 97.7% specificity, 75% positive predictive value. The ML model was superior in all performance metrics to the KFRE 4- and 8-variable models. eGFR and glucose were found to be highly contributing to the ESKD prediction performance. Conclusions: The computational predictions had higher accuracy, specificity and positive predictive value, which indicates the potential integration into clinical workflows for decision support.
AB - Background and Objectives: Chronic kidney disease progression to ESKD is associated with a marked increase in mortality and morbidity. Its progression is highly variable and difficult to predict. Methods: This is an observational, retrospective, single-centre study. The cohort was patients attending hospital and nephrology clinic at The Canberra Hospital from September 1996 to March 2018. Demographic data, vital signs, kidney function test, proteinuria, and serum glucose were extracted. The model was trained on the featurised time series data with XGBoost. Its performance was compared against six nephrologists and the Kidney Failure Risk Equation (KFRE). Results: A total of 12,371 patients were included, with 2,388 were found to have an adequate density (three eGFR data points in the first 2 years) for subsequent analysis. Patients were divided into 80%/20% ratio for training and testing datasets. ML model had superior performance than nephrologist in predicting ESKD within 2 years with 93.9% accuracy, 60% sensitivity, 97.7% specificity, 75% positive predictive value. The ML model was superior in all performance metrics to the KFRE 4- and 8-variable models. eGFR and glucose were found to be highly contributing to the ESKD prediction performance. Conclusions: The computational predictions had higher accuracy, specificity and positive predictive value, which indicates the potential integration into clinical workflows for decision support.
KW - XGBoost (Extreme Gradient Boosting)
KW - chronic kidney disease
KW - end stage kidney disease (ESKD)
KW - machine learning (ML)
KW - prediction model
UR - http://www.scopus.com/inward/record.url?scp=85127527036&partnerID=8YFLogxK
U2 - 10.3389/fmed.2022.837232
DO - 10.3389/fmed.2022.837232
M3 - Article
SN - 2296-858X
VL - 9
JO - Frontiers in Medicine
JF - Frontiers in Medicine
M1 - 837232
ER -